COMMUNIQUÉS West-GlobeNewswire

Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
08/08/2019
DUBLIN, Ireland, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today [...]
Cronos Group Inc. Announces Second Quarter and First-Half 2019 Results
08/08/2019
Opened Cronos Device Labs, New Global R&D Center in Israel Appointed Dr. Todd Abraham as Chief Innovation Officer Announced Agreement to Acquire State-of-the-Art Fermentation Facility Established New Growth [...]
Neos Therapeutics Reports Second Quarter 2019 Financial Results
08/08/2019
– Company to host conference call today at 8:30am EDT – DALLAS and FORT WORTH, Texas, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its [...]
Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
08/08/2019
Both STRIDE-1 Phase 3 trial in TRD and GEMINI Phase 3 trial in MDD for AXS-05 on track for readout of topline results in 2H 2019 MOMENTUM Phase 3 trial of AXS-07 in migraine on track for readout of topline results in 2H [...]
Novavax Scientific Leadership to Present New RSV Maternal Immunization Program Phase 3 Data and Participate in Discussion on RSV at the 2019 IDSOG Annual Meeting
08/08/2019
GAITHERSBURG, Md., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Louis F. [...]
Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates
08/08/2019
2Q19 Galafold ® (migalastat) Revenue of $44.1M Represents Highest Quarterly Growth Since Launch Driven by Continued Strong Global Uptake Reiterating FY19 Revenue Guidance of $160M-$180M Full Enrollment in Pompe Pivotal [...]
Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study
08/08/2019
NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today [...]
Kamada Reports Discussions with Takeda Regarding a Potential Extension of the Period for the Transition of GLASSIA Manufacturing to Takeda
08/08/2019
REHOVOT, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, reports that it is currently in discussions with Takeda to extend the period [...]
ReWalk Robotics Reports Second Quarter 2019 Financial Results
08/08/2019
— 2019 second quarter total revenue of $0.9 million — — Received FDA & CE clearance for ReStore Exo-Suit — YOKNEAM ILIT, Israel / MARLBOROUGH, Mass., Aug. 08, 2019 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: [...]
Rockwell Medical, Inc. Announces Completion of Two Clinical Pharmacology Studies of TRIFERIC® in China
08/08/2019
– Positive data suggests no ethnic difference in Triferic PK in Chinese subjects compared to U.S. subjects – – China studies indicate similar delivery of iron via dialysate as in U.S. studies – WIXOM, Mich., Aug. 08, [...]
Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®
08/08/2019
OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB ) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting the safety of using [...]
TCR² Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
08/08/2019
Began dosing of TC-210 in the Phase 1/2 trial for patients with mesothelin-expressing solid tumors and an interim update anticipated in 4Q19/1Q20 Leading clinical sites participating in the TC-210 trial include Sarah [...]
Reata Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results and an Update on Development Programs
08/08/2019
Conference Call With Management Scheduled for Today, August 8, 2019 IRVING, Texas, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today [...]
Protalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update
08/08/2019
CARMIEL, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]
Mersana Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Updates
08/08/2019
Patient Dosing in XMT-1536 Phase 1 Expansion Study Expected to Commence in Third Quarter 2019 Ended Second Quarter 2019 with $128 Million in Cash CAMBRIDGE, Mass., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics [...]
Genesis Healthcare Reports Solid Second Quarter 2019 Results
08/08/2019
KENNETT SQUARE, Pa., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Genesis Healthcare, Inc. (Genesis, or the Company) (NYSE:GEN), one of the largest post-acute care providers in the United States, today announced operating results [...]
RadNet Reports Second Quarter Financial Results and Increases Financial Guidance Levels
08/08/2019
Revenue increased 18.3% to $289.1 million in the second quarter of 2019 from $244.4 million in the second quarter of 2018 Adjusted EBITDA (1) increased 13.0% to $43.1 million in the second quarter of 2019 from $38.2 [...]
Evoke Pharma to Resubmit Gimoti™ NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results
08/08/2019
NDA resubmission anticipated in fourth quarter 2019 SOLANA BEACH, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for [...]
Novo Nordisk A/S - Share repurchase programme
08/08/2019
Bagsværd, Denmark, 8 August 2019 – On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]

Pages